Last reviewed · How we verify
cyclosporine ophthalmic emulsion
Cyclosporine ophthalmic emulsion works by suppressing the immune system to prevent rejection of transplanted corneal tissue.
Cyclosporine ophthalmic emulsion works by suppressing the immune system to prevent rejection of transplanted corneal tissue. Used for Prevention of corneal transplant rejection.
At a glance
| Generic name | cyclosporine ophthalmic emulsion |
|---|---|
| Sponsor | Vanderbilt-Ingram Cancer Center |
| Drug class | immunosuppressant |
| Target | calcineurin |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
It does this by inhibiting calcineurin, a key enzyme in the activation of T-lymphocytes. This results in a decrease in the production of cytokines, which are molecules that promote inflammation and immune response. By reducing inflammation, cyclosporine ophthalmic emulsion helps to prevent graft rejection and promote healing in the cornea.
Approved indications
- Prevention of corneal transplant rejection
Common side effects
- Eye irritation
- Blurred vision
- Eye pain
Key clinical trials
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy (PHASE2)
- Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis (NA)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclosporine ophthalmic emulsion CI brief — competitive landscape report
- cyclosporine ophthalmic emulsion updates RSS · CI watch RSS
- Vanderbilt-Ingram Cancer Center portfolio CI